Dose dependent changes in fluorescence and forward scatter from cyanobacteria treated with H₂O₂. حسب Emma T. Brentjens (17295999)

Pattern of <i>M</i>. <i>aeruginosa</i> fluorescence change with exposure to 750 μg/mL H₂O₂. حسب Emma T. Brentjens (17295999)

Fluorescence intensity curves of <i>M</i>. <i>aeruginosa</i> treated with PSII inhibitory chemicals from violet, blue, and yellow-green laser excitation. حسب Emma T. Brentjens (17295999)

Dose- and time-dependent response of <i>M</i>. <i>aeruginosa</i> fluorescence to H₂O₂ exposure. حسب Emma T. Brentjens (17295999)

"…In contrast, the percentage of cells treated with low dose (7.5 μg/mL) H₂O₂ found in the control region decreased each day and remained around 30% on day 8.…"

Ratio of forward scatter (FSC) and side scatter (SSC) to control in <i>M</i>. <i>aeruginosa</i> exposed to H₂O₂ and UV, blue, and green light. حسب Emma T. Brentjens (17295999)

Cyanobacteria growth of treated and control cells. حسب Emma T. Brentjens (17295999)

H₂O₂-treated <i>M</i>. <i>aeruginosa</i> forward scatter (FSC) and side scatter (SSC) relative to control. حسب Emma T. Brentjens (17295999)

Fluorescence intensity curves of control and 750 μg/mL H₂O₂ <i>M</i>. <i>aeruginosa</i> samples from UV, violet, blue, yellow-green, and red laser excitation.... حسب Emma T. Brentjens (17295999)

Fluorescence intensity curves of control and 750 μg/mL H₂O₂ <i>M</i>. <i>aeruginosa</i> samples from UV, violet, blue, yellow-green, and red laser excitation.... حسب Emma T. Brentjens (17295999)

<i>M</i>. <i>aeruginosa</i> treatment chemicals and doses. حسب Emma T. Brentjens (17295999)

Mean red and green fluorescence intensity data from three experiments of cyanobacteria. حسب Emma T. Brentjens (17295999)

Log reactivation results for exposures by 222 nm or 265 nm with or without UV-A 365 nm pre-treatment. حسب Daniel Ma (12698752)

Demographics and baseline characteristics of the safety population. حسب Rahsan Erdem (11726357)

الموضوعات:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. حسب Rahsan Erdem (11726357)

الموضوعات:

Grading of stool consistency and diarrhea severity. حسب Rahsan Erdem (11726357)

الموضوعات:

Secondary efficacy endpoints for the modified intent-to-treat population. حسب Rahsan Erdem (11726357)

الموضوعات:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for Fig 1. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for S1 and S2 Figs. حسب Rahsan Erdem (11726357)

الموضوعات:

Source data for Fig 2. حسب Rahsan Erdem (11726357)

الموضوعات: